Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Jin Yang Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,056	1,780	5,118	753.56	11,720	5,175
Short-Term Investments	1,000	-	2,600	7,890	120	-
Trading Asset Securities	174.83	233.78	877.27	1,851	3,035	149.75
Cash & Short-Term Investments	4,230	2,013	8,595	10,494	14,875	5,325
Cash Growth	-62.27%	-76.58%	-18.09%	-29.45%	179.33%	-2.40%
Accounts Receivable	25,726	26,098	21,711	19,885	16,670	13,465
Other Receivables	454.52	399.99	76.11	63.14	42.37	1,677
Receivables	26,180	26,498	21,788	20,248	17,012	15,441
Inventory	14,402	14,623	17,353	15,423	9,060	7,874
Prepaid Expenses	44.16	57.15	44.01	42.83	35.76	31.12
Other Current Assets	766.64	162.97	248.99	120.07	21.97	40.17
Total Current Assets	45,623	43,355	48,029	46,329	41,005	28,712
Property, Plant & Equipment	43,294	43,494	44,136	43,794	39,363	27,761
Long-Term Investments	1,243	1,243	3,087	4,279	4,238	2,778
Other Intangible Assets	5,631	5,043	4,886	3,573	1,870	1,510
Long-Term Accounts Receivable	-	-	-	0	-0	0
Long-Term Deferred Tax Assets	-	-	-	-	-	529.05
Long-Term Deferred Charges	1,103	1,188	1,630	1,407	-	-
Other Long-Term Assets	132,931	132,951	17,838	15,062	12,025	10,301
Total Assets	230,126	227,574	119,907	114,444	98,502	71,591
Accounts Payable	3,850	4,206	2,444	2,536	265.09	2,724
Accrued Expenses	2,522	2,534	2,554	2,245	2,061	2,537
Short-Term Debt	1,357	2,781	7,525	19,530	19,822	6,000
Current Portion of Long-Term Debt	1,200	1,200	-	-	-	-
Current Portion of Leases	190.64	221.68	207.76	198.45	113.92	100.03
Current Income Taxes Payable	740.04	998.77	1,374	1,442	678.45	297.84
Current Unearned Revenue	16.39	13.96	8.9	11.93	53.21	-
Other Current Liabilities	7,828	7,838	10,398	4,974	4,149	6,848
Total Current Liabilities	17,704	19,794	24,511	30,938	27,143	18,507
Long-Term Debt	75,000	75,300	-	-	-	-
Long-Term Leases	177.78	179.24	98.45	253.46	76.7	40.99
Long-Term Deferred Tax Liabilities	9,944	9,707	4,550	4,757	3,688	-
Other Long-Term Liabilities	3,213	2,096	1,558	618	2,277	2,230
Total Liabilities	106,829	107,696	31,149	36,869	33,184	23,320
Common Stock	6,501	6,326	6,008	6,000	6,000	6,000
Additional Paid-In Capital	16,028	13,366	9,737	9,625	9,625	9,625
Retained Earnings	89,249	88,666	61,323	51,884	40,626	32,359
Treasury Stock	-5,643	-5,643	-5,643	-5,643	-3,069	-3,069
Comprehensive Income & Other	17,164	17,164	17,333	15,709	12,136	3,355
Shareholders' Equity	123,298	119,878	88,758	77,575	65,318	48,270
Total Liabilities & Equity	230,126	227,574	119,907	114,444	98,502	71,591
Total Debt	77,926	79,682	7,831	19,982	20,013	6,141
Net Cash (Debt)	-73,695	-77,668	764.1	-9,488	-5,138	-815.84
Net Cash Per Share	-6187.22	-6298.40	61.24	-705.79	-450.13	-72.99
Filing Date Shares Outstanding	11.78	11.43	10.79	10.78	11.18	11.18
Total Common Shares Outstanding	11.78	11.43	10.79	10.78	11.18	11.18
Working Capital	27,920	23,561	23,518	15,391	13,862	10,205
Book Value Per Share	10469.50	10490.95	8224.03	7199.14	5843.71	4318.53
Tangible Book Value	117,666	114,834	83,871	74,002	63,448	46,761
Tangible Book Value Per Share	9991.34	10049.58	7771.28	6867.59	5676.41	4183.48
Land	27,379	27,366	26,901	23,983	19,589	8,381
Buildings	18,906	18,906	18,906	18,906	18,906	18,906
Machinery	20,004	19,700	19,272	18,782	19,455	16,675
Construction In Progress	-	86.6	32	1,157	448.88	748.88

Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.